Reduced risk of peanut sensitization following exposure through breast-feeding and early peanut introduction

Tracy J Pitt1, Allan B Becker2, Moira Chan-Yeung3

  • 1Humber River Hospital, Toronto, Ontario, Canada.

Insights

Maternal peanut consumption during breastfeeding combined with early infant introduction of peanuts significantly lowers peanut allergy risk. Avoiding peanuts or delaying introduction increases sensitization risk.

Area of Science:

  • Allergy and Immunology
  • Pediatric Nutrition
  • Epidemiology

Background:

  • Previous studies indicated that avoiding peanuts in infancy increases allergy risk.
  • However, the impact of maternal peanut consumption during breastfeeding was not addressed.

Purpose of the Study:

  • To investigate the relationship between maternal peanut consumption during breastfeeding and infant peanut introduction timing.
  • To assess the association with peanut sensitization at age 7 years.

Main Methods:

  • Secondary analysis of a nested cohort from the 1995 Canadian Asthma Primary Prevention Study.
  • Maternal and infant peanut consumption data collected via questionnaires during infancy.
  • Peanut sensitization assessed by skin prick testing at age 7 years.

Main Results:

  • Lowest peanut sensitization incidence (1.7%) observed when mothers consumed peanuts while breastfeeding and introduced peanuts to infants before 12 months.
  • Higher incidence noted if mothers consumed peanuts but delayed infant introduction (15.1%) or avoided peanuts while infants were introduced early (17.6%).
  • Combined maternal and infant peanut consumption was protective; isolated exposure increased sensitization risk (P interaction = .003).

Conclusions:

  • Maternal peanut consumption during breastfeeding coupled with early infant peanut introduction (by 12 months) is linked to the lowest risk of peanut sensitization.
  • This combination appears more protective than other maternal and infant consumption patterns.
Abstract

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
353
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
356
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276